191 related articles for article (PubMed ID: 27458279)
1. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
Pal SK; Agarwal N; Boorjian SA; Hahn NM; Siefker-Radtke AO; Clark PE; Plimack ER
J Clin Oncol; 2016 Sep; 34(27):3346-8. PubMed ID: 27458279
[No Abstract] [Full Text] [Related]
2. A precision, personalized approach to the management of bladder cancer.
Apolo AB; Burger M
Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
[No Abstract] [Full Text] [Related]
3. Precision and predictive medicine in urothelial cancer: are we making progress?
Bellmunt J; Orsola A; Sonpavde G
Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
[TBL] [Abstract][Full Text] [Related]
4. Genetic subtypes of invasive bladder cancer.
McConkey DJ; Choi W; Dinney CP
Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
[TBL] [Abstract][Full Text] [Related]
5. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology of urothelial carcinoma.
Lopez-Beltran A; Cimadamore A; Montironi R; Cheng L
Hum Pathol; 2021 Jul; 113():67-83. PubMed ID: 33887300
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
[TBL] [Abstract][Full Text] [Related]
8. Preface on application of omics technologies in cancer biology and therapy.
Georgakilas AG
Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153
[No Abstract] [Full Text] [Related]
9. High-depth sequencing of paired primary and metastatic tumours: Implications for personalised medicine.
Grellety T; Lucchesi C; Hostein I; Auzanneau C; Khalifa E; Soubeyran I; Italiano A
Eur J Cancer; 2017 Oct; 84():250-256. PubMed ID: 28841542
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
Jones RT; Felsenstein KM; Theodorescu D
Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
[TBL] [Abstract][Full Text] [Related]
12. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
13. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
[TBL] [Abstract][Full Text] [Related]
14. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
15. Personalising the treatment of prostate cancer.
Gunjur A
Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
[No Abstract] [Full Text] [Related]
16. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
17. Maurie Markman on the Groundbreaking TAPUR Trial.
Markman M
Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
[No Abstract] [Full Text] [Related]
18. Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.
Heide T; Maurer A; Eipel M; Knoll K; Geelvink M; Veeck J; Knuechel R; van Essen J; Stoehr R; Hartmann A; Altmueller J; Graham TA; Gaisa NT
J Pathol; 2019 Jun; 248(2):230-242. PubMed ID: 30719704
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?
Kohn EC
Am Soc Clin Oncol Educ Book; 2014; ():139-47. PubMed ID: 24857070
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
[Next] [New Search]
